GSA Capital Partners LLP Makes New Investment in DENTSPLY SIRONA Inc. $XRAY

GSA Capital Partners LLP acquired a new position in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) during the 4th quarter, HoldingsChannel.com reports. The institutional investor acquired 83,770 shares of the medical instruments supplier’s stock, valued at approximately $957,000.

Several other institutional investors have also recently bought and sold shares of XRAY. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in DENTSPLY SIRONA during the first quarter worth $26,000. Huntington National Bank raised its holdings in shares of DENTSPLY SIRONA by 292.9% in the third quarter. Huntington National Bank now owns 2,786 shares of the medical instruments supplier’s stock valued at $35,000 after purchasing an additional 2,077 shares during the last quarter. Caitong International Asset Management Co. Ltd raised its holdings in shares of DENTSPLY SIRONA by 337.9% in the third quarter. Caitong International Asset Management Co. Ltd now owns 2,750 shares of the medical instruments supplier’s stock valued at $35,000 after purchasing an additional 2,122 shares during the last quarter. Farther Finance Advisors LLC raised its holdings in shares of DENTSPLY SIRONA by 119.1% in the fourth quarter. Farther Finance Advisors LLC now owns 3,773 shares of the medical instruments supplier’s stock valued at $43,000 after purchasing an additional 2,051 shares during the last quarter. Finally, Clearstead Advisors LLC raised its holdings in shares of DENTSPLY SIRONA by 210.4% in the third quarter. Clearstead Advisors LLC now owns 8,319 shares of the medical instruments supplier’s stock valued at $106,000 after purchasing an additional 5,639 shares during the last quarter. Institutional investors and hedge funds own 95.70% of the company’s stock.

Insider Buying and Selling at DENTSPLY SIRONA

In other news, Director James D. Forbes bought 5,000 shares of the firm’s stock in a transaction that occurred on Monday, March 9th. The shares were bought at an average cost of $12.48 per share, with a total value of $62,400.00. Following the completion of the purchase, the director directly owned 10,000 shares in the company, valued at $124,800. This represents a 100.00% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, Director Gregory T. Lucier bought 27,555 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The stock was purchased at an average cost of $14.24 per share, for a total transaction of $392,383.20. Following the completion of the purchase, the director owned 27,555 shares of the company’s stock, valued at $392,383.20. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders purchased 70,000 shares of company stock worth $956,437. 0.50% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on XRAY shares. Wells Fargo & Company increased their target price on shares of DENTSPLY SIRONA from $12.00 to $13.00 and gave the company an “equal weight” rating in a report on Friday, February 27th. Barrington Research increased their target price on shares of DENTSPLY SIRONA from $14.00 to $17.00 and gave the company an “outperform” rating in a report on Monday, March 2nd. Weiss Ratings downgraded shares of DENTSPLY SIRONA from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 6th. Mizuho lowered their target price on shares of DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating for the company in a report on Wednesday, May 6th. Finally, Zacks Research upgraded shares of DENTSPLY SIRONA from a “strong sell” rating to a “hold” rating in a research report on Monday, March 2nd. Three analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $13.82.

DENTSPLY SIRONA Trading Up 2.8%

XRAY stock opened at $10.21 on Friday. The company has a market capitalization of $2.05 billion, a PE ratio of -3.24, a price-to-earnings-growth ratio of 1.18 and a beta of 0.93. DENTSPLY SIRONA Inc. has a one year low of $9.40 and a one year high of $17.09. The company’s 50 day moving average price is $11.42 and its two-hundred day moving average price is $11.81. The company has a debt-to-equity ratio of 1.52, a quick ratio of 0.98 and a current ratio of 1.53.

DENTSPLY SIRONA (NASDAQ:XRAY) last posted its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.27 EPS for the quarter, missing the consensus estimate of $0.28 by ($0.01). The business had revenue of $880.00 million for the quarter, compared to analysts’ expectations of $841.80 million. DENTSPLY SIRONA had a positive return on equity of 18.83% and a negative net margin of 17.06%.The company’s revenue was up .1% compared to the same quarter last year. During the same period last year, the business posted $0.43 earnings per share. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. As a group, analysts predict that DENTSPLY SIRONA Inc. will post 1.42 earnings per share for the current fiscal year.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.